Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
about
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Our 2015 approach to invasive pulmonary aspergillosis.Azole antifungals: 35 years of invasive fungal infection management.The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.Posaconazole: An Update of Its Clinical Use.Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension.
P2860
Q33798313-CFD04A0F-9BBD-49B7-87C9-EED3B04A1177Q34299092-1405A042-D362-45AD-AA5A-EAAC7C881E91Q34596750-E4E1DF2D-164C-4D0B-82C6-97753B5DCD83Q35860057-64642592-E2A1-4951-9189-D04FE2BCB691Q37203849-AF3E0DA9-4A77-4F60-853E-1B9F58D22489Q37335720-86629863-258D-4EE8-8411-6BB53D670D24Q38284468-2D824183-1130-4F64-98DF-97A988F641CBQ38391049-611852E8-8028-4162-8A1F-2E54C523FA52Q38406393-758E7B4B-4C0F-4292-A285-2BB368A5AF25Q40255550-8A37AFD9-E549-4BC5-BF10-76310A20C00CQ40892430-3128DC60-9276-4FB7-B682-CA9DC5BBD84CQ41291872-6D0BCBBE-5867-4BC5-A50C-5708DAD86B09Q41993016-256F5D20-3327-4FE3-9D96-78D2ACD3743BQ42144246-CB2D624A-8A40-4147-967F-A8A1F0800DD1Q44162406-1A651DC1-1158-4CDD-9941-3E0000D32A03Q53073458-830C1DF4-4F8E-42B0-AF49-889AF4784BEA
P2860
Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacokinetics of different ...... for invasive fungal infection.
@ast
Pharmacokinetics of different ...... for invasive fungal infection.
@en
type
label
Pharmacokinetics of different ...... for invasive fungal infection.
@ast
Pharmacokinetics of different ...... for invasive fungal infection.
@en
prefLabel
Pharmacokinetics of different ...... for invasive fungal infection.
@ast
Pharmacokinetics of different ...... for invasive fungal infection.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of different ...... for invasive fungal infection
@en
P2093
Amelia Langston
David Helfgott
Gopal Krishna
Jörg-Janne Vehreschild
Maria J G T Vehreschild
Michael C McCarthy
Susan Huyck
P2860
P304
P356
10.1128/AAC.05937-11
P407
P577
2012-01-30T00:00:00Z